Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 13 tags : Vaccine save search
Worldwide Vaccine Industry to 2027 - Key Drivers, Restraints and Opportunities
Published: 2021-10-13 (Crawled : 19:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 400K
|
Manufacturing
|
| O: 1.46%
H: 0.0%
C: -0.4%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.32%
H: 0.9%
C: 0.25%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.28%
H: 0.06%
C: -0.49%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 1.2%
H: 0.08%
C: -0.43%
NVAX | $4.15 -0.96% -0.96% 2M
|
Health Technology
|
| O: 2.18%
H: 2.72%
C: -0.16%
vaccine
Africa vaccine Market In-Detailed Analysis and Growth and Huge Competition on Moderna Inc., Innovative Biotech, Biovaccines Nigeria Limited | Says Brandessence Market Research
Published: 2021-10-13 (Crawled : 13:00) - prnewswire.com
BNTX | News | $88.09 -0.45% -0.35% 230K
|
Health Technology
|
| O: 1.35%
H: 1.58%
C: 0.94%
ce mark biotech vaccine growth research iot africa
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
Published: 2021-10-13 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.16 1.13% -20.84% 0
|
Communications
|
| O: -0.18%
H: 0.0%
C: 0.0%
IBRX | $4.82 -12.2% -14.02% 7.4M
|
Manufacturing
|
| O: 0.54%
H: 0.59%
C: -2.15%
phase 2 cancer vaccine pancreatic pancreas enroll
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
VBIV | $0.59 -3.04% -3.26% 130K
|
Health Technology
|
| O: 0.99%
H: 2.28%
C: -0.33%
hepatitis results vaccine phase 3
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Published: 2021-10-13 (Crawled : 11:00) - biospace.com/
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: 0.04%
H: 0.14%
C: -0.44%
covid multiple sclerosis disease antibody vaccine sclerosis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.